HCDM Council


Prof. Menno C. van Zelm, PhD
HCDM council president and IUIS Nomenclature Chair
Dept. Immunology and Pathology Monash University and Alfred Hospital Melbourne, VIC, Australia
E: This email address is being protected from spambots. You need JavaScript enabled to view it.
W: www.monash.edu/medicine/ccs/
immunology/research/vanzelm-lab

Prof. Tomáš Kalina, MD.,Ph.D.
HCDM Nomenclature Vice-Chair
Dept. of Paediatric Hematology/Oncology 
2nd Faculty of Medicine, Charles University, Prague, Czech Republic
E: This email address is being protected from spambots. You need JavaScript enabled to view it.
W: www.lf2.cuni.cz/clip/

Prof. Pablo Engel
HCDM past-president
Immunology Unit, Department of Biomedical Sciences, Medical School University of Barcelona, Spain
Assoc. Prof. Georgina Clark, Ph.D.
Aznac Research Institute, University of Sydney, Australia
E: This email address is being protected from spambots. You need JavaScript enabled to view it.
W: www.anzac.edu.au/research/dcbtg/

Univ. Prof. Dr. Hannes Stockinger
Institute for Hygiene and Applied Immunology Center for Pathophysiology, Infectiology and Immunology Medical University of Vienna, Vienna, Austria
E: This email address is being protected from spambots. You need JavaScript enabled to view it.
W: www.meduniwien.ac.at/hai

Valter Gattei, MD
Clinical and Experimental Onco-Hematology Unit Centro di Riferimento Oncologico, I.R.C.C.S. Aviano, Italy
E: This email address is being protected from spambots. You need JavaScript enabled to view it.

Antonio Cosma, PhD, HDR
Luxembourg Institute of Health, Luxembourg
E. This email address is being protected from spambots. You need JavaScript enabled to view it.
W: www.lih.lu/en/national-cytometry-platform/
Paula Fernandez, Dr. med. Dr phil. II
Kantonsspital Aarau AG, Switzerland
E: This email address is being protected from spambots. You need JavaScript enabled to view it.
W: www.ksa.ch/team-facs-labor

Aja Rieger, PhD
University of Alberta, Edmonton, Alberta, Canada
Prof. Dr. Hyun Dong Chang
German Rheumatism Research Center Berlin, Berlin, Germany
W: www.drfz.de/en/forschung/pb1/ag/schwiete-labor-fuer-mikrobiota-und-entzuendung/

The HLDA Workshops

For each Workshop, antibodies are submitted to the organising laboratory where they are coded and sent to testing laboratories. These laboratories test the antibodies against various cell types, blind – ie without knowing what reactivity is expected. The testing laboratories return the results to the organising laboratory for analysis. This approach selects for robust reagents – antibodies that work under a variety of experimental conditions.

Another important feature of the Workshops has been distribution of antibodies to laboratories with specialised skills such as functional studies, epitope mapping, tissue distribution, disease associations. In this way information on novel molecules has accumulated rapidly.

History

Studies of leucocyte surface molecules have been organised through a series of international Workshops known as the Human Leucocyte Differentiation Antigens (HLDA) Workshops.

When the HLDA Workshops started, monoclonal antibodies against leucocyte markers were relatively new and large numbers of new antibodies were being produced in a number of laboratories. It was difficult to know which antibodies were against the same molecules.

The first HLDA Workshop and Conference, held in Paris in 1982, evaluated and compared many of these antibodies. The characteristic approach of the 1st and subsequent HLDA Workshops was multi-laboratory blind analysis of antibodies. This approach has provided independent validation of antibody specificity and usability, and has underpinned the confident use of these reagents in research, diagnosis and therapy.

The CD nomenclature, (groups of antibodies with a similar reaction pattern nominated as "Clusters of Differentiation", CD), and the characterised molecules CD1 to CD350, have been derived from these Workshops. CD antibodies are used widely for research, differential diagnosis, monitoring and treatment of disease.

Over the course of the HLDA Workshops, there have been several advances which have affected the mission of the HCDM:

  • Whereas in the first few HLDA Workshops antibodies were used to define and characterise new molecules, new techniques mean that molecules are now generally first identified by molecular genetics or proteomics, and antibodies are made subsequently
  • The focus of studies to understand immune responses has increasingly taken into condsideration the understanding that the immune system does not act in isolation and immunologists need to study and understand the cells with which immune cells interact, such as endothelial cells and stromal cells
  • The realisation that, while cell surface molecules are central to the interactions between immune cells and their environment, the function of these molecules is mediated by intracellular molecules which can provide (also unique) useful markers of differentiation, activation and lineage.
  • Whereas one of the important drivers of the original HLDA Workshops was the lack of a useful nomenclature for cell surface markers, the CD nomenclature now exists in the context of agreed gene nomenclature, and to some extent competes with it.

In recognition of these factors, the HCDM Council resolved to extend studies to stromal cells and other cells of interest to immunological studies, to extend studies (but not the CD nomenclature) to intracellular molecules, and to allocate CD names when there was a need for a name rather than to all cell surface molecules of the immune system.

HCDM Sponsors: